V

VistaGen Therapeutics Inc
NASDAQ:VTGN

Watchlist Manager
VistaGen Therapeutics Inc
NASDAQ:VTGN
Watchlist
Price: 2.82 USD -3.75% Market Closed
Market Cap: 76.3m USD
Have any thoughts about
VistaGen Therapeutics Inc?
Write Note

EV/EBIT
Enterprise Value to EBIT

0.8
Current
-0.2
Median
3.8
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
0.8
=
Enterprise Value
-32.1m USD
/
EBIT
-38.2m USD
All Countries
Close
EBIT Growth
US
V
VistaGen Therapeutics Inc
NASDAQ:VTGN
Average EV/EBIT: 20.2
0.8
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -214 322.8 N/A
US
Abbvie Inc
NYSE:ABBV
22.8
88%
US
Amgen Inc
NASDAQ:AMGN
33.7
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -507.3 N/A
AU
CSL Ltd
ASX:CSL
26
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.4
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.1 N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
0.5
2-Years Forward
EV/EBIT
0.4
3-Years Forward
EV/EBIT
0.4

See Also

Discover More